Loncastuximab (Anti-CD19)

Loncastuximab (Anti-CD19) is a recombinant monoclonal antibody targeting CD19. It shows antitumor activity and has potential application in non-Hodgkin's lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL). The antibody-drug conjugate (ADC) Loncastuximab tesirine, marketed under the brand name Zynlonta, is a medicine used to treat certain types of B-cell lymphomas, specifically relapsed or refractory large B-cell lymphoma and high-grade B-cell lymphoma. This ADC drug is a conjugate that combines a monoclonal antibody Loncastuximab, linker and cytotoxic drug (PBD). It works by targeting the CD19 protein on the surface of B-cell tumors, and delivering a cytotoxic drug (PBD) that kills the cancer cells. This biosimilar antibody is used for research only. MW :144.38 KD.

Product Details
Species Reactivity	Human
Host/Isotype	Human IgG1
Class	Monoclonal
Type	Recombinant Antibody
Immunogen	Human CD19
Clone	Loncastuximab biosimilar
Conjugate	Unconjugated
Purity	99%
Molecular Weight	144.38 KD
Protein Concentration	1mg/ml
Storage Condition	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.
Storage Buffer	100mM Pro-Ac, 20mM Arg-Ac, pH 5.0